NCT07582419Not yet recruiting
Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
Hybrid Deep Learning Models Based on Multimodal CEUS and Enhanced MRI Can Optimize Treatment Decisions for Early-stage Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
This study aims to address the issue of a lack of individualized basis for selecting liver resection (LH) or microwave ablation (MWA) in early-stage hepatocellular carcinoma (HCC) patients to reduce the early recurrence rate (≤2 years). Given that existing machine learning-based recurrence prediction studies have failed to guide the optimal treatment plan selection, and that multidisciplinary consultations rely on guidelines (universality) and experience (subjectivity) which have their limitations, we propose to utilize artificial intelligence (AI), specifically the advantages of multimodal deep learning technology (which outperforms traditional machine learning by integrating complementary information to provide more accurate predictions), to establish a hybrid deep learning model that integrates contrast-enhanced ultrasound (CEUS) and enhanced magnetic resonance imaging (MRI) features. This model will predict the probability of early recurrence (ER≤2 years) in patients and, based on this, recommend LH or MWA as the optimal first treatment option for newly diagnosed early HCC patients to optimize individualized treatment decisions.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1424 (estimated)
- First submitted
- 26 Apr 2026
- Start date
- 30 Apr 2026
- Primary completion date
- 30 Oct 2027
- Lead sponsor
- The First Hospital of Jilin University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07582419
What you commit to
- Study type: Observational
- Planned participants: 1424
- From 30 Apr 2026 to the primary completion date, 30 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 2: History of other treatments prior to surgery;
Other illness
- 1：There is already extrahepatic metastasis or the presence of other malignant tumors;
Other
- 3: Incomplete preoperative ultrasound contrast and/or MRI imaging data, with images missing or unclear;
- 4: Missing postoperative follow-up data
Who the study is looking for
- Preoperative enhanced imaging examination or pathological diagnosis is HCC;
- CNLC Stage I, IIa, Child-Pugh Class A/B;
- A single tumor with a diameter ≤ 5 cm or 2-3 tumors, with the maximum diameter ≤ 3 cm;
- Perform liver resection surgery or MWA surgery treatment;
- MRI and/or CEUS examinations performed within one month before surgery
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.